Populational studies have pointed out that, in CKD patients, the increase in FGF-23 and PTH, accompanied by the decrease in 1,25 dihydroxyvitamin D3, anticipate hyperphosphatemia [54], which is often observed in these patients and is usually related to a higher mortality risk among them [55,56,57]. This evidence concerns the gene PTH and hyperphosphatemia.